Cellectis develops allogeneic CAR-T cell therapies for cancer using its proprietary TALEN gene-editing technology. The company engineers T-cells from healthy donors to create off-the-shelf immunotherapies designed for broad patient applicability rather than individualized treatments. Its clinical pipeline targets relapsed or refractory B-cell malignancies such as acute lymphoblastic leukemia and non-Hodgkin lymphoma, with additional programs in other cell and gene therapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 10.7 | — | -18.1 | — |
| Q2 2025 | 16.7 | — | -23.7 | — |
| Q3 2025 | 35.2 | — | 0.6 | — |
| Q4 2025 | 10.4 | — | -26.3 | — |
| Q1 2026 | 5.8 | -45.8% | -17.8 | — |
| Q2 2026 | 5.2 | -68.7% | -21.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Viemed Healthcare, Inc. (VMD), Bold Eagle Acquisition Corp. (BEAG), Cadiz Inc. (CDZI), Sutro Biopharma, Inc. (STRO), Blue Water Acquisition Corp. III (BLUW), Abeona Therapeutics Inc. (ABEO)